Showing 243 results

Filters Content type: News, Editors' picks, About HIV Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

New & experimental HIV treatments

China to approve 1st long-acting injection to treat HIV/AIDS

Editor's pick
Global Times
25 November 2016
New & experimental HIV treatments

ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen

Editor's pick
ViiV press release
21 November 2016
PrEP science

The ‘long tail’ problem: injected-PrEP trial will be extended due to persistence of drug in companion study

News
11 November 2016
New & experimental HIV treatments

Ibalizumab monoclonal antibody looks promising for people with drug-resistant HIV

News
4 November 2016
New & experimental HIV treatments

New long-acting fusion inhibitor albuvirtide plus boosted protease inibitor matches standard triple-drug therapy

News
28 October 2016
PrEP

More Surprises From ÉCLAIR: Cabotegravir's 'Long Tail'

Editor's pick
Medscape (requires free registration)
26 October 2016
New & experimental HIV treatments

Long-acting injectable drugs work well for HIV maintenance therapy

News
22 July 2016
New & experimental HIV treatments

The HIV Treatment Pipeline

Editor's pick
Poz
28 June 2016
New & experimental HIV treatments

Frontier Biotech's Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

Editor's pick
Frontier Biotech press release
7 June 2016
New & experimental HIV treatments

Long-acting oral antiretroviral MK-8591 could represent 'paradigm shift' in HIV treatment and prophylaxis

News
1 April 2016
PrEP

What is a drug “tail,” and what does it have to do with long-acting PrEP?

Editor's pick
BETA blog
25 February 2016
New & experimental HIV treatments

Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy

News
23 February 2016
New & experimental HIV treatments

IV and Injectable HIV Treatments Are Much Discussed -- But Won't Be Here Anytime Soon

Editor's pick
TheBody Pro
21 January 2016
New & experimental HIV treatments

Janssen, ViiV Healthcare Formalize Injectable Rilpivirine + Cabotegravir Phase 3 as HIV Treatment

Editor's pick
Street Insider
8 January 2016
Injectable & long-acting HIV treatment

Long-acting injectable HIV treatment shows promise in early study results

Editor's pick
Science Speaks
4 November 2015
New & experimental HIV treatments

Cabotegravir and rilpivirine effective for HIV maintenance therapy at 96 weeks

News
19 March 2015
Injectable & long-acting PrEP

Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine

News
30 October 2014
New & experimental HIV treatments

Drug-level study shows feasibility of long-acting integrase inhibitor cabotegravir

Editor's pick
HIVand hepatitis.com
10 September 2014
Injectable & long-acting HIV treatment

Long-acting HIV drugs advanced to overcome adherence challenge

Editor's pick
Nature Medicine
8 April 2014
New & experimental HIV treatments

Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation

News
8 March 2014
PrEP

Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

Editor's pick
The Body Pro
6 October 2013
Injectable & long-acting HIV treatment

Long-acting antiretrovirals may improve survival for people with poor adherence

News
4 October 2013
New & experimental HIV treatments

Good safety profile with long-acting integrase inhibitor, GSK744

Editor's pick
NATAP
19 September 2013
New & experimental HIV treatments

Long-acting GSK1265744 and TMC278-LA appear safe and practical in early study

News
5 July 2013